Exelixis | EXEL - 应收帐款人



金融业
股票价格
USD
资产
USD 2.49B
现金及等价物
USD 281.45M
销售成本
USD 20.66M
流动资产
USD 1.25B
流动负债
USD 361.93M
债务
USD 165.93M
EBIT
USD 248.41M
EBITDA
USD 255.4M
员工
1.15K
EPS每股收益
USD 0.91
股本和储备
USD 1.84B
销售毛利
USD 608.03M
债务利息支出
USD 23.4M
利息收入
USD 14.21M
市值
USD 16.68B
净收入
USD 212.05M
营业费用
USD 380.28M
营业利润
USD 248.41M
普通股股本
USD 248.89M
PE价格收益
18.02
税前利润
USD 262.68M
销售收入
USD 628.69M
销售和管理费用
USD 147.63M
股票
USD 28.73M
贸易债权人
USD 39.06M
应收帐款人
USD 322.21M


应收帐款人 更改 日
Acadia Pharmaceuticals USD 166.33M 17.95M 2026-06
Agios Pharmaceuticals USD 16.13M 5.56M 2026-03
Akebia Therapeutics USD 47.03M 19.19M 2025-12
Amgen USD 10.23B 1.09B 2026-06
AstraZeneca USD 18.86B 972M 2026-06
Bayer EUR 18.7B 146M 2026-06
BioMarin Pharmaceutical USD 1.06B 157.13M 2026-06
Bristol-Myers Squibb USD 13.83B 535M 2026-06
Cytokinetics USD 6.83M 10.94M 2026-03
Eisai JPY 253.13B 26.12B 2026-06
Eli Lilly USD 23.48B 2.3B 2026-06
Exelixis USD 322.21M 6.73M 2026-06
Genmab DKK 1.22B 192M 2026-06
Glaxosmithkline GBP 10.49B 40.6M 2026-03
Incyte USD 1.13B 73.7M 2026-06
Ionis Pharmaceuticals USD 58.84M 15.16M 2026-06
MacroGenics USD 10.42M 2.95M 2026-03
Merck USD 12.21B 435M 2026-03
Moderna USD 17M 54M 2026-06
Nektar Therapeutics USD 3.6M 1.82M 2026-03
Neurocrine Biosciences USD 887M 118.9M 2026-06
Novartis USD 9.85B 252M 2026-06
Pfizer USD 16.19B 19M 2026-06
Puma Biotechnology USD 28.1M 3.52M 2024-06
Sanofi EUR 482M 85M 2026-03
Takeda JPY 956.14B 79.79B 2026-06
Ultragenyx Pharmaceutical USD 60M 98M 2026-03
Xencor USD 42.23M 30.23M 2026-06